{"entity":{"id":"eli-002-7p","kind":"drug","name":"ELI-002 7P","aka":[],"tldr":"A ready-made vaccine against the seven commonest KRAS mutations, given after pancreatic cancer surgery. Its phase 2 missed the main goal in 2026 but showed signs of activity.","summary":"Elicio's amphiphile peptides (7 mKRAS antigens) plus CpG adjuvant, engineered to drain to lymph nodes. Phase 1 AMPLIFY-201 induced mKRAS-specific T cells in most patients with ctDNA reductions. Randomised phase 2 AMPLIFY-7P (adjuvant PDAC, results June 2026) did not meet its primary DFS endpoint in the intent-to-treat population; post-hoc landmark analyses reported ~14% absolute DFS benefit during active treatment. Elicio is refining a phase 3 strategy around R0-resected patients.","status":"phase-2","asOf":"2026-09-06","links":[{"label":"Elicio AMPLIFY-7P results (June 2026)","url":"https://elicio.com/press_releases/elicio-therapeutics-reports-results-from-phase-2-amplify-7p-study-and-outlines-refined-phase-3-development-strategy-for-eli-002-7p-in-adjuvant-pancreatic-cancer/"}],"tags":[],"related":[],"cancers":["pancreatic","resectable-pdac","colorectal"],"sections":[],"technologies":["shared-antigen-vaccine","mrd-testing"],"targets":["kras"],"drugs":[],"companies":["elicio-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["amplify-7p"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Off-the-shelf lymph-node-targeted KRAS peptide vaccine","mechanism":"Albumin-binding lipid tails carry mutant-KRAS peptides to lymph nodes for dendritic cell presentation.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/eli-002-7p/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"elicio-therapeutics","kind":"company","name":"Elicio Therapeutics","route":"/companies/elicio-therapeutics/"}],"trial":[{"id":"amplify-7p","kind":"trial","name":"AMPLIFY-7P","route":"/trials/amplify-7p/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"},{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"}],"term":[{"id":"pancreatic-failed-programmes","kind":"term","name":"Pancreatic cancer: the failed and stopped programmes and why","route":"/terms/pancreatic-failed-programmes/"}],"bottleneck":[{"id":"b-undruggable-targets","kind":"bottleneck","name":"The undruggable drivers","route":"/bottlenecks/b-undruggable-targets/"}]}}